Another study investigated the use of the DNA methyltransferase inhibitor azacytidine alongside pembrolizumab and noted an increased number of CD8+ tumor-infiltrating lymphocytes in mCRC compared with that in the pre-treated condition (162). The gene discussed is CD8A; the disease is neoplasm.